https://doi.org/10.1016/s0140-6736(20)32531-9
T
Tsutomu Iwasa
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
4.1K
Citations
28
h-index
58
i10-index
Tsutomu Iwasa is an academic researcher from Kindai University Hospital. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 28, co-authored 136 publications.
ORCID: 0000-0001-5996-0602Papers by this author
worksPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · The Lancet · 1,743 citations
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
2019 · Scientific Reports · 213 citations
https://doi.org/10.1038/s41598-019-50099-y
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
2008 · British Journal of Cancer · 101 citations
https://doi.org/10.1038/sj.bjc.6604222
Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
2010 · British Journal of Cancer · 65 citations
https://doi.org/10.1038/sj.bjc.6605713
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
2024 · Journal of Clinical Investigation · 34 citations
https://doi.org/10.1172/jci168318
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
2022 · European Journal of Cancer · 31 citations
https://doi.org/10.1016/j.ejca.2022.05.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat